Minor histocompatibility antigen HA-1 peptide presented by HLA class I (HA-1 (when referring to the peptide); HLA class I (for the presenting molecule); no unified standard abbreviation for the complex)

The minor histocompatibility antigen HA-1 peptide presented by HLA class I refers to a specific peptide epitope (originating from the HMHA1 gene and processed intracellularly) that is bound and displayed on the cell surface by human leukocyte antigen (HLA) class I molecules. This peptide-HLA complex is recognized by CD8+ cytotoxic T lymphocytes, triggering immune responses against cells presenting the HA-1 peptide. The HA-1 antigen is strongly immunogenic and plays a pivotal role in alloimmune responses after stem cell transplantation, where its selective expression on hematopoietic cells makes it a prime therapeutic target for T cell-mediated immunotherapy against hematological malignancies while minimizing off-target effects on non-hematopoietic tissues. It is not a receptor, enzyme, or transporter, but rather a peptide/MHC complex central to immunological recognition in the context of transplantation and immune oncology[2][4][9].

Other names

HA-1 peptideHematopoietic antigen HA-1Human minor histocompatibility antigen HA-1HA-1/HLA class I complex

Targeted by cytotoxic T lymphocytes (CTLs) for immune recognition and killing of cells presenting the HA-1 peptide in the context of HLA class I, typically in allogeneic transplantation immunotherapy or immunosurveillance.